Managing Treatment-Resistant Depression

Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD.

• Defines Treatment-Resistant Depression and Staging Treatment Intensity
• Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions
• Discusses the use of Ketamine and Esketamine for treatment-resistant depression

Contenu

1. Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity
   
   2. Clinical and epidemiological predictors of treatment-resistant depression
   3. The economic burden of treatment-resistant depression: Cost-of-illness perspective
   4. The neurobiology of treatmentresistant depression
   5. Modeling treatment-resistant depression in the preclinical setting
   6. Treatment algorithms for treatment-resistant depression
   7. Tools to aid precision treatments to prevent or manage treatmentresistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
   8. Tricyclic antidepressants for treatment-resistant depression
   9. Monoamine oxidase inhibitors for treatment-resistant depression
   10. Switching antidepressants in patients with treatment-resistant depression
   11. Adjunctive strategies for treatment-resistant depression
   12. Combining antidepressants to address treatment-resistant depression
   13. Ketamine/esketamine for treatment-resistant depression
   14. Psychedelic agents for treatmentresistant depression
   15. Inflammation and treatment resistance: Mechanisms and treatment implications
   16. Opioid agents for treatmentresistant depression
   17. Transcranial magnetic stimulation for treatment-resistant depression
   18. tDCS for treatment-resistant depression
   19. ECT for treatment-resistant depression
   20. MST for treatment-resistant depression
   21. VNS for treatment-resistant depression
   22. Deep brain stimulation for treatment-resistant depression
   23. Other neurosurgical interventions for treatment-resistant depression
   24. Treatment-resistant psychotic depression
   25. Evidence-based psychotherapy for treatment-resistant depression
   26. Treatment-resistant bipolar depression
   27. Treatment-resistant depression in child and adolescents
   28. Treatment-resistant depression in geriatrics
   29. Identification and management of anxious depression in patients with treatment-resistant depression
   30. Managing treatment-resistant depression with comorbid personality disorders
   31. Managing treatment-resistant depression with comorbid substance use disorders
   32. Managing treatment-resistant depression in the setting of chronic pain
   33. Inhaled gases for treatmentresistant major depression
   34. Drugs under investigation for treatment-resistant depression
   35. Chronotherapeutics for treatmentresistant depression
   36. Managing treatment resistant depression in primary care settings
   37. Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
   38. Lifestyle interventions for treatment-resistant depression
   39. Managing the risk of suicide in people with treatment-resistant depression
   40. Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatmentresistant depression